PHARMACEUTICALS

Our portfolio of sublingual pharmaceutical products is built on the WaferiX platform technology, and includes pipeline products in the late stage of development

No.
Active
Indication
Clinical Studies
Pharmaceuticals
Pre Clinical
P1
P2
P3
Marketing Approval
1
Wafesil Sildenafil
Male erectile dysfunction
2
Silcap Sildenafil
Male erectile dysfunction
3
Wafermine Ketamine
Acute pain
4
IXB-214 Ketamine
Complex Regional Pain Syndrome
5
IXB-314 Ketamine
Treatment resistant depression
6
BnoX Buprenorphine
Moderate to severe pain

Wafermine

World’s first sublingual ketamine for acute moderate to severe pain.

Phase 3-ready

Non-opioid with opioid sparing effects
Positive in Phase 2b clinical studies:

  • Strong analgesic effect
  • Safe and tolerable
LEARN MORE

Bnox

Improved bioavailability from other sublingual buprenorphine products.

By utilising iX Biopharma’s proprietary sublingual technology WaferiX, we have demonstrated in a phase 1 pharmacokinetic study (BUP001) that BnoX facilitates the rapid absorption of buprenorphine (median Tmax 1.0 hour) with greater absolute bioavailability of 45%. These results suggest superior pharmacokinetics to currently marketed sublingual buprenorphine formulations.

LEARN MORE

Wafesil & Silcap

Sildenafil for the treatment of erectile dysfunction in unique dosage forms.

Sildenafil citrate has been shown to be a hallmark drug for the treatment of erectile dysfunction in males. Utilising WaferiX, Wafesil is a sildenafil wafer that is administered sublingually. Wafesil comes in a new dosage form and route of administration for patients who cannot or prefer not to swallow. Wafesil is approved for marketing in Australia, outlicensed for China market.

Silcap is a novel small sildenafil capsule that is easy to swallow. Silcap is approved for marketing in Australia and Singapore.

Scientific Publications